This is a PDF-only article. The first page of the PDF of this article appears below.
Current Issue
Article Tools
Share this Article
- Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein BPermalink:
Related Articles
Cited By...
- Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
- New Era of Lipid-Lowering Drugs
- Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans
- Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
- Mechanistic Understanding for the Greater Sensitivity of Monkeys to Antisense Oligonucleotide-Mediated Complement Activation Compared with Humans
- Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo-Controlled Study of Healthy Volunteers
- Lomitapide and Mipomersen: Two First-in-Class Drugs for Reducing Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia
- Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk: A Randomized, Double-Blind, Placebo-Controlled Trial
- When should we measure lipoprotein (a)?
- Antithrombotic Effect of Antisense Factor XI Oligonucleotide Treatment in Primates
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
- Low-Density Lipoprotein Lowering in 2013 by Nonstatin Agents: The Discovery and Development of Promising Novel Targeted Therapies
- Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia: Results of a Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety as Add-On Therapy in Patients With Coronary Artery Disease
- Target mRNA inhibition by oligonucleotide drugs in man
- Unique O-Methoxyethyl Ribose-DNA Chimeric Oligonucleotide Induces an Atypical Melanoma Differentiation-Associated Gene 5-Dependent Induction of Type I Interferon Response
- Antisense oligonucleotides for the treatment of dyslipidaemia
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial
- A new approach to managing the 'statin-intolerant' patient?
- Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
- Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice
- Reversal of Hyperlipidemia With a Genetic Switch Favorably Affects the Content and Inflammatory State of Macrophages in Atherosclerotic Plaques
- Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk
- Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
- Short-term effect of cocoa product consumption on lipid profile: a meta-analysis of randomized controlled trials
- Does inhibition of apolipoprotein B synthesis produce foie gras?
- Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
- Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice
- Errata. PCSK9 function and physiology
- PCSK9 function and physiology
- Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
- ISIS 301012 Gene Therapy for Hypercholesterolemia: Sense, Antisense, or Nonsense?
- The Year in Atherothrombosis
- Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
- Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100
- Human RNase H1 Discriminates between Subtle Variations in the Structure of the Heteroduplex Substrate